HomeREGULATORY
REGULATORY

Opdivo’s Gastric Cancer Use, Avelumab and More Up for MHLW Panel Review/Report on Sept. 8
(Aug.28.2017)

Opdivo
The health ministry will report to its key advisory committee on September 8 a plan to approve Ono Pharmaceutical’s PD-1 inhibitor Opdivo (nivolumab) for a new indication of gastric cancer, with its official green light expected within a month or so thereafter - a move that threatens the revocation of a sakigake designation granted for the drug’s archrival Keytruda (pembrolizumab) ...
(LOG IN FOR FULL STORY)

News Calendar